AtaiBeckley

What AtaiBeckley does

AtaiBeckley is a clinical-stage biopharmaceutical company formed in November 2025 through the all-share combination of atai Life Sciences and Beckley Psytech, headquartered in New York and incorporated in Delaware following a December 2025 redomiciliation from the Netherlands. The company develops psychedelic-based neuroplastogens targeting mental health indications with significant unmet need, primarily treatment-resistant depression (TRD) and social anxiety disorder (SAD), with an earlier discovery program in opioid use disorder. Its lead asset, BPL-003, is a proprietary intranasal formulation of mebufotenin benzoate (5-MeO-DMT) granted FDA Breakthrough Therapy designation in October 2025, designed to produce rapid and durable antidepressant effects from a single dose within a two-hour interventional psychiatry paradigm; a Phase 3 ReConnection program is planned to initiate in Q2 2026 with topline data targeted for early 2029. The pipeline also includes VLS-01, a buccal film formulation of DMT for TRD in Phase 2, and EMP-01, an oral R-MDMA formulation for SAD that reported positive Phase 2a data in February 2026.

The company is pre-revenue from product sales, with Q1 2026 revenue of approximately $954,000 reflecting collaboration or grant receipts and operating cash burn of roughly $101.6 million per quarter. Capital sources include a $149.5 million public offering (October 2025), an up to $175 million term loan facility with Hercules Capital, and an up to $11.4 million NIDA grant. Management has publicly engaged Jefferies and JPMorgan to explore strategic options for BPL-003, including a potential sale or partnership targeting $2 billion or more. The product economics under discussion assume a projected net annual price of approximately $30,000 for BPL-003 at launch around 2030, with peak unadjusted US sales forecasts of $3.7 billion for BPL-003 and $2.6 billion for VLS-01 in 2036. Distribution is expected to occur through clinical settings with healthcare professional administration, and the company is investing in patient advocacy, including a multi-year collaboration with PsyPAN, to shape interventional psychiatry delivery models ahead of commercialization.

Name

AtaiBeckley

Legal name

AtaiBeckley Inc.

Website

https://ataibeckley.com

Company type

Public

Founded year

2025

Operating status

Operating

Headcount range

101–250 employees

Short description

AtaiBeckley is a clinical-stage biopharmaceutical company developing psychedelic-based neuroplastogens, led by BPL-003 (intranasal 5-MeO-DMT with FDA Breakthrough Therapy designation), VLS-01 (buccal DMT film), and EMP-01 (oral R-MDMA), targeting treatment-resistant depression, social anxiety disorder, and opioid use disorder.

Ownership category

akta.pro rank

Product category

Clinical-stage psychedelic mental health therapeutics

NAICS

Medicinal and Botanical Manufacturing (325411)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Psychedelic mental health therapies
• Treatment-resistant depression drugs
• Clinical-stage biopharmaceuticals
• Neuroplastogen drug development
• Interventional psychiatry treatments

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Pre-revenue clinical-stage company. Expected to commercialize BPL-003, VLS-01, and EMP-01 upon regulatory approval. Pricing model projects net annual price of $30,000 for BPL-003 at launch with peak unadjusted U.S. sales of $3.7 billion for BPL-003 and $2.6 billion for VLS-01 in 2036.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Core offering

AtaiBeckley is a clinical-stage biopharmaceutical company developing proprietary psychedelic-based neuroplastogen therapies for mental health conditions with significant unmet need. Its pipeline includes intranasal mebufotenin benzoate (BPL-003), buccal DMT film (VLS-01), oral R-MDMA (EMP-01), and an early-stage program targeting novel 5-HT2A receptor agonists, all designed to deliver rapid, durable treatment effects within a two-hour interventional psychiatry paradigm.

Product overview

AtaiBeckley is a clinical-stage biopharmaceutical company formed in 2025 through the strategic combination of atai Life Sciences and Beckley Psytech. The company operates as a unified platform developing a portfolio of psychedelic-based neuroplastogens for mental health conditions. Its core product pipeline includes: BPL-003 (mebufotenin benzoate intranasal formulation for treatment-resistant depression in Phase 2), VLS-01 (DMT buccal film for treatment-resistant depression in Phase 2), EMP-01 (oral R-MDMA for social anxiety disorder in Phase 2), and a Discovery program developing novel 5-HT2A receptor agonists including non-hallucinogenic compounds for opioid use disorder and TRD. All lead products are designed to produce rapid, robust, and durable treatment effects within a two-hour interventional psychiatry treatment paradigm.

Differentiator

Problem solved

Functional benefit

Products and services

• BPL-003 (Mebufotenin Benzoate) A proprietary synthetic intranasal formulation of mebufotenin benzoate (5-MeO-DMT) being developed as a rapid-acting, durable treatment for treatment-resistant depression, designed for administration within a two-hour interventional psychiatry treatment paradigm with FDA Breakthrough Therapy designation.
• VLS-01 (Buccal Film DMT)

Quantifiable outcome

• 66.7% response rate at Day 2 among treatment-resistant depression patients receiving single dose of BPL-003
• +5 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered minor and core.

• PsileraminorStrategic or Co-development Partner · 28 May 2026Strategic licensing agreement with Psilera for DMT patent portfolio, along with up to $2 million in NIH funding support for Psilera's neuroplastogen PSIL-006 development. Positions Psilera to transition from discovery-stage to clinical-stage organization.
• Psychedelic Participant Advocacy Network (PsyPAN)coreStrategic or Co-development Partner · 27 April 2026Multi-year collaboration on participant-informed psychedelic clinical research including qualitative workshops, published white paper titled 'The Participants in Their Own Words,' and 12-month independent peer-support pilot program for UK participants. Expanded to include international patient advocacy organizations and academic collaborators at King's College London and University of Exeter.
• Beckley Psytech LimitedcoreStrategic or Co-development Partner · 5 November 2025Strategic combination of atai Life Sciences and Beckley Psytech completed on November 5, 2025, forming AtaiBeckley as a global leader in psychedelic mental health therapies. Combined pipeline includes BPL-003, VLS-01, and EMP-01 across treatment-resistant depression and social anxiety disorder indications.

Scale indicators10 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• GH Research: Clinical-stage biopharmaceutical company developing mebufotenin (5-MeO-DMT) therapies for treatment-resistant depression, the same molecular target and indication as AtaiBeckley's BPL-003, making it the most direct head-to-head competitor in the psychedelic CNS space.
• Compass Pathways: Clinical-stage company developing psilocybin therapy (COMP360) for treatment-resistant depression, with Phase 3 programs underway. Direct competitor in psychedelic therapeutics for TRD, with overlapping patient population and clinical development strategy.
• MindMed: Clinical-stage psychedelic medicine biotech developing lysergic acid diethylamide (LSD) and MDMA-based therapies for anxiety, depression, and ADHD. Comparable pipeline of psychedelic-based neuroplastogens targeting CNS indications with similar clinical-stage risk profile.
• Cybin: Clinical-stage psychedelics company developing proprietary deuterated psilocybin analog (CYB003) for major depressive disorder and other CNS indications. Comparable psychedelic biotech with overlapping clinical-stage programs in depression.

Broad incumbents

• Axsome Therapeutics: Commercial-stage CNS specialty biopharma with Auvelity (dextromethorphan/bupropion) approved for major depressive disorder. Comparable CNS specialty pharma with overlapping depression indication, though with established commercial revenue and a non-psychedelic mechanism.
• Sage Therapeutics: CNS-focused biopharmaceutical company with Zurzuvae (zuranolone) approved for postpartum depression, a neuroactive steroid with rapid-onset antidepressant properties. Comparable CNS specialty pharma targeting depression with differentiated non-psychedelic mechanism.
• Johnson & Johnson: Large pharmaceutical company with Spravato (esketamine) approved for treatment-resistant depression, the first FDA-approved rapid-acting antidepressant with a psychedelic-adjacent mechanism. Most directly relevant commercial-stage competitor in the interventional psychiatry treatment paradigm.
• Eli Lilly: Major pharmaceutical company with extensive CNS/depression portfolio including fluoxetine (Prozac) and active development of next-generation antidepressants. Relevant incumbent with deep CNS expertise and large commercial infrastructure that could compete with or potentially acquire psychedelic assets.

Emerging players

• Seelos Therapeutics: Clinical-stage biopharmaceutical company developing psychedelic-based therapies (SLS-002 intranasal racemic ketamine) for suicidality and other CNS indications. Comparable smaller psychedelic biotech with adjacent interventional psychiatry focus.
• Neumora Therapeutics: Clinical-stage CNS biopharma developing novel therapeutics for depression and other brain disorders, with pipeline assets including NMRA-140 (M4 muscarinic agonist) for schizophrenia. Comparable clinical-stage CNS biotech targeting high-unmet-need psychiatric indications.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/ataibeckley

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Subsidiaries1 record

Funding overview

Funding rounds14 records

Investors45 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A6 records

Investments19 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AtaiBeckley